Will Thibeau

Will Thibeau is a policy analyst in the Tech Policy Center at The Heritage Foundation. In this role, Will drives policy research and recommendations related to “Big Tech.” Topics for public engagement include antitrust action, data privacy, and free discourse policies.

Before joining Heritage, Will worked at The American Conservative (TAC), where he was senior director of operations. At TAC, he spearheaded two major events, “Up From Chaos” and “Crony Capitalism.” Crony Capitalism, an event with Senator Ron Johnson, was banned across multiple tech platforms.

In addition to this experience with Big Tech censorship, Will brings a wealth of tech knowledge and expertise from his years at Palantir, where he delivered artificial intelligence and machine learning software to the military.

Before Palantir, Will was a U.S. Army Infantry Officer with the 75th Ranger Regiment. As a Ranger, Will deployed in support of the Global War on Terror multiple times.

He possesses a tech skillset that includes DevOps, data management, and IT asset management. He is a graduate of Fordham University.

Will lives in Northern Virginia with his wife, Michelle, and their children.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent
Read More

Universities, Patents, and the Future of U.S. Competitiveness

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties
Read More

How Counterfeit Drugs Threaten U.S. Health and Innovation

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor
Read More